import type { Metadata } from "next";
import Link from "next/link";
import ArticleLayout from "@/components/ArticleLayout";

export const metadata: Metadata = {
  title:
    "Healthcare Private Label Marketing: How Pharmacy Chains Are Disrupting Branded Products",
  description:
    "A strategic guide to private label competition in pharmacy retail. Covers why chains like Nahdi and Al-Dawaa invest in own brands, which categories are most vulnerable, how branded companies should respond, and co-manufacturing as an opportunity. Written from 20+ years in GCC pharma.",
  openGraph: {
    title:
      "Healthcare Private Label Marketing: How Pharmacy Chains Are Disrupting Branded Products",
    description:
      "How pharmacy private label products are disrupting branded OTC, supplements, and skincare in KSA and GCC. Defense strategies and co-manufacturing opportunities for pharma companies.",
    type: "article",
    authors: ["Sherif Al-Kady"],
  },
  keywords: [
    "private label healthcare marketing",
    "pharmacy private label strategy",
    "private label OTC products",
    "Nahdi private label brands",
    "Al-Dawaa own brand products",
    "pharmacy store brands KSA",
    "private label vitamins supplements",
    "branded vs private label pharma",
    "co-manufacturing pharmacy brands",
    "private label marketing strategy GCC",
  ],
};

export default function PrivateLabelArticle() {
  return (
    <ArticleLayout
      title="Healthcare Private Label Marketing: How Pharmacy Chains Are Disrupting Branded Products"
      description="A strategic guide to private label competition in pharmacy retail. Covers why chains like Nahdi and Al-Dawaa invest in own brands, which categories are most vulnerable, how branded companies should respond, and co-manufacturing as an opportunity. Written from 20+ years in GCC pharma."
      author="Sherif Al-Kady, MBA"
      date="March 23, 2026"
      readTime="12 min read"
      category="Strategy"
      slug="private-label-healthcare-marketing"
      publishedDate="2026-03-23"
      heroImage="/images/blog-hero-private-label.png"
      heroImageAlt="Pharmacy shelf showing branded versus private label healthcare products"
      faqItems={[
        {
          question: "Why are pharmacy chains launching private label healthcare products?",
          answer: "Pharmacy chains launch private label products to capture higher margins (typically 40-60% gross margin vs 20-30% on branded products), build customer loyalty, differentiate their offering, and reduce dependence on branded suppliers. Nahdi, Al-Dawaa, and Whites in KSA have all accelerated private label development as part of their profitability strategies.",
        },
        {
          question: "Which consumer healthcare categories are most vulnerable to private label?",
          answer: "The categories most vulnerable to private label in KSA pharmacies are vitamins and supplements, topical antiseptics, basic wound care, nasal sprays, and generic OTC analgesics. Categories with strong brand equity and clinical differentiation — like branded dermocosmetics and clinically-proven therapeutic brands — are more resilient.",
        },
        {
          question: "How should branded pharma companies respond to private label competition?",
          answer: "Branded pharma companies should respond to private label competition by strengthening clinical differentiation, investing in pharmacist recommendation programs, building direct consumer loyalty through digital channels, focusing on categories where efficacy evidence is non-replicable, and evaluating co-manufacturing agreements as a revenue opportunity.",
        },
        {
          question: "Can pharma companies benefit from making private label products for pharmacy chains?",
          answer: "Yes. Co-manufacturing private label products for pharmacy chains can be a viable revenue stream for pharma companies with excess manufacturing capacity. It provides volume, cash flow, and strategic relationship value with major chains — provided it does not cannibalize core branded business or create pricing floor conflicts.",
        },
      ]}
    >
      <p>
        Every branded pharma company operating in the GCC has felt it &mdash;
        that moment when you walk into a Nahdi or Al-Dawaa store and see your
        category&rsquo;s shelf space quietly shrinking. Not because a competitor
        launched a better product. Because the pharmacy chain itself launched a
        cheaper one with its own name on the box.
      </p>
      <p>
        This is not a hypothetical scenario. It is happening right now across
        vitamins, supplements, personal care, oral care, and basic OTC
        categories in Saudi Arabia, the UAE, and beyond. Pharmacy chains are
        investing aggressively in private label &mdash; and they are getting
        better at it every quarter.
      </p>
      <p>
        I have spent more than 20 years building and defending consumer
        healthcare brands across the GCC. I have sat across the table from
        category managers who told me outright that their private label margins
        are double what my branded product delivers. I have watched premium
        brands lose 15&ndash;20% volume share in a single year to a store brand
        that did not exist the year before. And I have helped companies fight
        back &mdash; sometimes by competing harder, sometimes by turning private
        label into an opportunity rather than a threat.
      </p>
      <p>
        This article is the strategic guide I wish I had when I first faced
        this challenge. Whether you are defending a legacy brand or considering
        co-manufacturing for a chain, you will find practical frameworks here
        that you can act on immediately.
      </p>

      {/* Private Label Stats */}
      <div className="not-prose grid grid-cols-2 sm:grid-cols-4 gap-3 my-8">
        {[
          { value: "40–60%", label: "Gross margin on private label vs. 20–30% on branded products" },
          { value: "15–20%", label: "Volume share a brand can lose in 1 year to a new store brand" },
          { value: "3×", label: "Faster growth in vitamins/supplements private label vs. category average" },
          { value: "SAR 2B+", label: "Estimated value of private label healthcare in KSA by 2027" },
        ].map((stat) => (
          <div key={stat.label} className="rounded-xl bg-gradient-to-br from-navy-800 to-navy-900 border border-white/10 p-4 text-center">
            <p className="text-2xl font-bold text-accent-500 mb-1">{stat.value}</p>
            <p className="text-xs text-navy-400 leading-snug">{stat.label}</p>
          </div>
        ))}
      </div>

      <hr />

      <h2>Table of Contents</h2>
      <ul>
        <li>The Rise of Private Label in Healthcare</li>
        <li>Why Pharmacy Chains Invest in Private Label</li>
        <li>Categories Most Vulnerable to Private Label Disruption</li>
        <li>How Branded Companies Should Respond</li>
        <li>Private Label Quality Perception and How to Compete</li>
        <li>The KSA Private Label Landscape: Nahdi, Al-Dawaa, and Kunooz</li>
        <li>Marketing Strategies to Defend Against Private Label</li>
        <li>Co-Manufacturing as an Opportunity</li>
        <li>Frequently Asked Questions</li>
      </ul>

      <hr />

      <h2>The Rise of Private Label in Healthcare</h2>
      <p>
        Private label is not a new concept. In grocery retail, store brands
        have been a fixture for decades. Tesco, Walmart, Carrefour, and
        Costco generate billions from their own-brand products. But healthcare
        has traditionally been slower to adopt private label &mdash; and for
        understandable reasons. When health is on the line, consumers want to
        trust what they are putting into their bodies. Brand names carry
        weight. Clinical heritage matters. The pharmacist&rsquo;s
        recommendation carries authority.
      </p>
      <p>
        What has changed &mdash; globally and in the GCC specifically &mdash;
        is that pharmacy chains have figured out how to overcome the trust
        barrier. They have invested in quality assurance, secured regulatory
        approvals from bodies like the SFDA, partnered with reputable contract
        manufacturers, and leveraged the institutional trust that consumers
        already place in the pharmacy brand itself. When a consumer trusts
        Nahdi as a healthcare institution, extending that trust to a
        Nahdi-branded vitamin supplement becomes a much shorter cognitive leap
        than it would be for an unknown generic brand.
      </p>

      <h3>The Global Picture</h3>
      <p>
        In the United States, store-brand health and wellness products account
        for roughly 22&ndash;28% of category sales by volume. In the UK,
        Boots&rsquo; own-brand health products are a multi-billion-pound
        business. In Germany, where consumers are both quality-conscious and
        value-oriented, private label penetration in pharmacy and drugstore
        channels exceeds 30% in several categories.
      </p>
      <p>
        The GCC is still in the early stages by comparison &mdash; private
        label penetration in health and wellness categories is estimated at
        8&ndash;14% across the region. But the trajectory is unmistakably
        upward. And if global patterns hold, the GCC will likely reach
        20&ndash;25% penetration within the next five to seven years. That
        represents a massive transfer of revenue from branded products to
        store brands.
      </p>

      <h3>The KSA Context</h3>
      <p>
        Saudi Arabia is the largest pharmacy market in the GCC, and it is where
        the private label movement is most advanced. Several structural factors
        are accelerating adoption. Vision 2030&rsquo;s push toward local
        manufacturing is reducing production costs for private label products.
        SFDA registration requirements apply equally to branded and private
        label products, giving consumers regulatory confidence in store brands.
        And the high smartphone penetration and e-pharmacy adoption rates mean
        that chains can use data to identify exactly which branded products are
        most vulnerable to substitution &mdash; and launch private label
        alternatives in precisely those segments.
      </p>

      <hr />

      <h2>Why Pharmacy Chains Invest in Private Label</h2>
      <p>
        Understanding the motivations behind private label programs is
        essential for any branded company that wants to craft an effective
        response. The reasons are not mysterious, but they are more
        multifaceted than most brand managers appreciate.
      </p>

      <h3>1. Margin Expansion</h3>
      <p>
        This is the most obvious and powerful driver. When a pharmacy chain
        sells a branded product, the gross margin typically ranges from
        18&ndash;28%, depending on the category, the brand&rsquo;s market
        power, and the negotiated trade terms. When the same chain sells its
        own private label product in the same category, the gross margin can
        reach 40&ndash;55%. That is not a marginal improvement &mdash; it is
        a structural shift in unit economics.
      </p>
      <p>
        A chain that moves just 10% of its category revenue from branded to
        private label can materially improve its bottom line without opening
        a single new store or acquiring a single new customer. The financial
        incentive is overwhelming, and it only grows as chains gain experience
        in sourcing, manufacturing, and marketing their own products.
      </p>

      <h3>2. Customer Loyalty and Differentiation</h3>
      <p>
        In a market where Nahdi, Al-Dawaa, and other chains sell many of the
        same branded products at comparable prices, differentiation is
        difficult. Private label solves this problem. A consumer who buys and
        trusts Nahdi-branded Vitamin D has a reason to keep shopping at Nahdi
        that transcends price and convenience. The store brand becomes an
        anchor that deepens the relationship between the retailer and the
        shopper.
      </p>
      <p>
        This is particularly powerful when combined with loyalty programs. A
        chain can offer bonus loyalty points on its own-brand products,
        creating a reinforcing cycle: the customer earns more rewards, returns
        more often, and buys more private label products each visit.
      </p>

      <h3>3. Supply Chain Control and Negotiation Leverage</h3>
      <p>
        Branded manufacturers control their own supply, pricing, and
        promotional calendars. This creates dependency for retailers. By
        developing private label alternatives, chains reduce their dependency
        on any single branded supplier. If a manufacturer raises prices,
        reduces trade margins, or experiences a supply disruption, the chain
        has a fallback. More importantly, the mere existence of a private
        label alternative gives the retailer strategic leverage in every
        negotiation with branded suppliers. The unspoken message is clear:
        we do not need you as much as you think.
      </p>

      <h3>4. Category Gap Filling</h3>
      <p>
        Sometimes the motivation is not about replacing branded products at
        all. If no branded player offers a specific formulation, price point,
        or format that consumers are asking for, the retailer can fill that
        gap faster than waiting for a brand to develop one. I have seen chains
        launch private label products in underserved niches &mdash; specific
        vitamin combinations, travel-sized supplements, Arabic-language
        packaging for traditional remedies &mdash; that no branded company had
        bothered to address.
      </p>

      <div className="table-wrapper">
        <table>
          <thead>
            <tr>
              <th>Driver</th>
              <th>Benefit to Retailer</th>
              <th>Threat Level to Branded</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Margin expansion</td>
              <td>40&ndash;55% gross margin vs. 18&ndash;28% on branded</td>
              <td>Very High</td>
            </tr>
            <tr>
              <td>Customer loyalty</td>
              <td>Unique products drive repeat visits and lock-in</td>
              <td>High</td>
            </tr>
            <tr>
              <td>Supply chain control</td>
              <td>Reduced dependency on branded suppliers</td>
              <td>Medium-High</td>
            </tr>
            <tr>
              <td>Category gap filling</td>
              <td>Faster response to unmet consumer demand</td>
              <td>Low-Medium</td>
            </tr>
          </tbody>
        </table>
      </div>

      <hr />

      {/* Private Label Vulnerability Bar Chart */}
      <div className="not-prose my-8 rounded-2xl border border-white/10 bg-navy-900/60 p-6">
        <p className="text-xs font-semibold text-accent-500 uppercase tracking-wider mb-1">Risk Assessment</p>
        <h3 className="text-white font-bold text-lg mb-5">Private Label Disruption Risk by Category — GCC Pharmacy</h3>
        <div className="space-y-3">
          {[
            { category: "Vitamins & Supplements", risk: 9.5, color: "#ef4444" },
            { category: "Antiseptics & Wound Care", risk: 9.0, color: "#ef4444" },
            { category: "Nasal Sprays (generic)", risk: 8.5, color: "#ef4444" },
            { category: "Analgesics (OTC)", risk: 8.0, color: "#ef4444" },
            { category: "Oral Care (basic)", risk: 7.0, color: "#f59e0b" },
            { category: "Baby Care (non-specialist)", risk: 6.5, color: "#f59e0b" },
            { category: "Dermocosmetics (branded)", risk: 4.0, color: "#00d4b8" },
            { category: "Clinically-proven Rx-adjacent", risk: 2.0, color: "#00d4b8" },
          ].map((item) => (
            <div key={item.category} className="flex items-center gap-3">
              <span className="text-sm text-navy-300 w-52 shrink-0">{item.category}</span>
              <div className="flex-1 bg-white/5 rounded-full h-2.5 overflow-hidden">
                <div className="h-full rounded-full" style={{ width: `${(item.risk / 10) * 100}%`, backgroundColor: item.color }} />
              </div>
              <span className="text-sm font-semibold text-white w-10 text-right">{item.risk}</span>
            </div>
          ))}
        </div>
        <p className="text-xs text-navy-500 mt-4">Risk score out of 10 — red = high disruption risk, teal = defensible with brand investment</p>
      </div>

      <h2>Categories Most Vulnerable to Private Label Disruption</h2>
      <p>
        Not all product categories face the same risk from private label. The
        categories where store brands thrive share specific characteristics:
        high purchase frequency, perceived ingredient or formulation
        commoditization, low emotional attachment to specific brands, and a
        price gap large enough to trigger switching behavior. Here is where
        the vulnerability is highest in GCC pharmacy retail.
      </p>

      <h3>Vitamins and Supplements</h3>
      <p>
        This is the category with the highest private label penetration in
        pharmacy channels globally, and the GCC is no exception. Vitamin C,
        Vitamin D, zinc, omega-3, and basic multivitamins are seen by many
        consumers as commodities. The consumer logic is simple: Vitamin D is
        Vitamin D &mdash; why pay SAR 45 for a branded version when the
        pharmacy&rsquo;s own brand offers the same ingredient at SAR 29? In
        the US, store-brand vitamins already exceed 20% category share by
        volume. The GCC is trending in the same direction.
      </p>

      <h3>Personal Care and Hygiene</h3>
      <p>
        Cotton pads, cotton buds, hand sanitizers, wet wipes, basic
        moisturizers, and lip balms are fertile ground for private label. These
        products are purchased frequently, the purchase decision is driven
        primarily by price and availability, and the perceived performance
        difference between brands is minimal. A private label hand sanitizer
        or pack of cotton pads at 30% below the branded price is an easy
        switch for most shoppers.
      </p>

      <h3>Basic OTC Medications</h3>
      <p>
        Paracetamol, ibuprofen, antacids, cough syrups, and allergy
        medications are increasingly being offered as private label products
        in markets where regulations allow it. In the GCC, the SFDA&rsquo;s
        evolving framework for OTC classification will determine how far
        pharmacy chains can go in this category. But the trend is clear: as
        regulatory pathways open up, private label will follow.
      </p>

      <h3>Skincare and Dermocosmetics</h3>
      <p>
        This category is more nuanced. Basic skincare &mdash; cleansers,
        basic moisturizers, sunscreen at commodity price points &mdash; is
        vulnerable. But specialized dermocosmetics with clinical positioning,
        patented active ingredients, and dermatologist endorsement remain
        relatively protected. The lesson here is that the level of clinical
        differentiation directly correlates with private label resistance.
        If your skincare product&rsquo;s value proposition is essentially
        &ldquo;it moisturizes,&rdquo; you are vulnerable. If it is
        &ldquo;clinically proven to reduce hyperpigmentation by 40% in 8
        weeks,&rdquo; you have a moat.
      </p>

      <h3>Oral Care</h3>
      <p>
        Basic toothbrushes, standard toothpaste, mouthwash, and dental floss
        are seeing growing private label competition. A pharmacy own-brand
        toothbrush at SAR 8 versus a branded one at SAR 15 is a compelling
        proposition for price-conscious shoppers. Premium oral care with
        patented technology &mdash; specialized whitening systems, prescription-
        grade fluoride products &mdash; retains defensibility. The commodity
        tier does not.
      </p>

      <div className="table-wrapper">
        <table>
          <thead>
            <tr>
              <th>Category</th>
              <th>Vulnerability Level</th>
              <th>Key Vulnerability Factor</th>
              <th>Branded Defense Difficulty</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Vitamins &amp; Supplements</td>
              <td>Very High</td>
              <td>Perceived ingredient commoditization</td>
              <td>High</td>
            </tr>
            <tr>
              <td>Personal Care &amp; Hygiene</td>
              <td>High</td>
              <td>Low brand loyalty, price-driven decisions</td>
              <td>Medium-High</td>
            </tr>
            <tr>
              <td>Basic OTC Medications</td>
              <td>Medium-High</td>
              <td>Active ingredient equivalence</td>
              <td>Medium</td>
            </tr>
            <tr>
              <td>Basic Skincare</td>
              <td>Medium-High</td>
              <td>Minimal perceived performance gap</td>
              <td>Medium</td>
            </tr>
            <tr>
              <td>Oral Care (basic tier)</td>
              <td>Medium</td>
              <td>Functional equivalence at lower price</td>
              <td>Medium</td>
            </tr>
          </tbody>
        </table>
      </div>

      <hr />

      <h2>How Branded Companies Should Respond</h2>
      <p>
        Here is the uncomfortable truth that I share with every brand team I
        work with: private label is not winning because it is better. It is
        winning because branded companies have not given consumers a compelling
        enough reason to pay the premium. The gap between your product&rsquo;s
        actual superiority and the consumer&rsquo;s perception of that
        superiority is exactly where private label thrives.
      </p>
      <p>
        Your job is to close that gap. Not by cutting price &mdash; that is a
        race to the bottom. But by making your premium undeniable.
      </p>

      <h3>Strengthen Your Value Proposition</h3>
      <p>
        The single most effective defense against private label is a product
        that genuinely cannot be replicated by a contract manufacturer working
        from a generic formulation brief. Proprietary delivery systems,
        patented ingredient combinations, clinically validated efficacy claims,
        unique bioavailability data &mdash; these are the moats that private
        label cannot cross. If your Vitamin D is formulated identically to
        every other Vitamin D on the market, the conversation will always come
        down to price. And you will lose that conversation every time.
      </p>

      <h3>Lead with Clinical Evidence</h3>
      <p>
        In healthcare categories, scientific credibility is your ultimate
        competitive advantage. Private label products rarely invest in clinical
        studies, peer-reviewed publications, or healthcare professional
        education programs. This is your territory. If your product has
        clinical data demonstrating superior bioavailability, faster onset
        of action, or better patient outcomes, make that data visible &mdash;
        to consumers, pharmacists, and physicians alike. A branded supplement
        with a published clinical trial is fundamentally different from a
        private label product with an identical ingredient list but zero
        clinical validation. You need to make that difference visible and
        tangible.
      </p>

      <h3>Build Brand Equity That Transcends the Product</h3>
      <p>
        Private label can copy your formulation. It cannot copy your brand.
        The brands most resilient against private label erosion are those with
        deep emotional connections to consumers &mdash; built through years of
        consistent communication, healthcare professional endorsement, and
        brand experiences that go beyond the product itself. Think about why
        parents choose a specific branded children&rsquo;s vitamin over the
        store brand. It is not just the ingredient list. It is trust, heritage,
        the pediatrician&rsquo;s recommendation, and the peace of mind that
        comes with choosing a name they recognize and believe in.
      </p>

      <h3>Invest in Direct Consumer Relationships</h3>
      <p>
        One of private label&rsquo;s structural advantages is that the
        retailer owns the consumer relationship. They have the loyalty data,
        the purchase history, and the ability to communicate directly through
        their app, email, and SMS channels. Branded companies have
        traditionally relied on the retailer as the intermediary. That has
        to change.
      </p>
      <p>
        Build your own consumer communities. Invest in content marketing that
        educates and engages. Use social media to create brand preference that
        consumers carry into the pharmacy with them. When a shopper walks into
        Nahdi already knowing they want your brand specifically, the private
        label product sitting next to it on the shelf becomes much less
        threatening.
      </p>

      <div className="takeaway">
        <p>
          <strong>Actionable takeaway:</strong> Audit every SKU in your
          portfolio and categorize each one by its defensibility against
          private label. Products with no meaningful differentiation beyond
          brand name need either a genuine product upgrade, a significant
          investment in brand equity building, or a pricing strategy
          reassessment. Ignoring the problem is not a viable option.
        </p>
      </div>

      <hr />

      <h2>Private Label Quality Perception and How to Compete</h2>
      <p>
        Five years ago, a pharmacy own-brand supplement would have been viewed
        with skepticism by most Saudi consumers. That perception has changed
        materially, driven by three factors that branded companies often
        underestimate.
      </p>
      <p>
        First, SFDA registration requirements apply equally to private label
        and branded products. When a consumer sees that a Nahdi-branded
        supplement carries the same SFDA registration as a premium branded
        one, the quality assurance becomes implicit. The regulatory stamp
        does not distinguish between brand tiers.
      </p>
      <p>
        Second, pharmacy chains have invested heavily in packaging quality
        that is often indistinguishable from branded products. Clean design,
        professional labeling, clear dosage information, bilingual
        Arabic-English text &mdash; the visual quality gap that used to signal
        &ldquo;cheap alternative&rdquo; has effectively closed in most
        categories.
      </p>
      <p>
        Third, and most importantly, the pharmacy chain itself carries
        significant brand equity. Nahdi is not an unknown name. It is a
        trusted healthcare institution with over 1,200 stores across the
        Kingdom. When Nahdi puts its name on a product, that institutional
        trust transfers. The same applies to Al-Dawaa, Whites, and other
        established chains across the GCC.
      </p>

      <h3>Where Trust Still Favors Branded Products</h3>
      <p>
        Despite the narrowing quality perception gap, there are categories
        where consumers still show a clear preference for established brands.
        Specialized dermocosmetics with dermatologist-backed positioning.
        Products for chronic conditions where the patient has an established
        relationship with the brand. Infant and child health products where
        parental anxiety drives a preference for recognized names. And any
        product where the healthcare professional has specifically recommended
        the branded version.
      </p>
      <p>
        The strategic implication is clear: if you are a branded company, you
        need to move your positioning closer to these trust-protected zones.
        The more your product resembles a commodity, the more vulnerable you
        are. The more it looks like a specialized, clinically validated,
        professionally recommended healthcare solution, the more protected
        you become.
      </p>

      <blockquote>
        <p>
          The brands that survive the private label wave are not the ones that
          cut prices. They are the ones that make their premium undeniable
          through genuine clinical differentiation, healthcare professional
          advocacy, and consumer trust that store brands cannot replicate.
        </p>
      </blockquote>

      <hr />

      <h2>The KSA Private Label Landscape: Nahdi, Al-Dawaa, and Kunooz</h2>
      <p>
        Understanding the specific private label strategies of the major KSA
        pharmacy chains is essential for any branded company operating in the
        Kingdom. Each chain approaches private label differently, and your
        competitive response should be tailored accordingly.
      </p>

      <h3>Nahdi Medical Company</h3>
      <p>
        Nahdi operates the most sophisticated private label program in GCC
        pharmacy retail. With over 1,200 stores and a dominant e-commerce
        platform, they have the scale, data, and consumer trust to build a
        formidable own-brand portfolio. Their private label range spans
        vitamins, supplements, personal care, baby care, and beauty &mdash;
        and it is expanding steadily.
      </p>
      <p>
        What makes Nahdi&rsquo;s approach particularly dangerous for branded
        companies is their use of first-party data from the Nuhdeek loyalty
        program. They can identify which branded products have the highest
        repeat purchase rates and the highest price sensitivity, and then
        develop private label alternatives in precisely those segments. This
        is data-driven disruption, and most branded companies do not have the
        tools to see it coming until their sell-out numbers start declining.
      </p>
      <p>
        Nahdi&rsquo;s private label products are typically positioned at
        25&ndash;35% below the branded equivalent. The quality perception is
        strong, supported by SFDA-compliant manufacturing, professional
        packaging, and the Nahdi brand halo.
      </p>

      <h3>Al-Dawaa Pharmacies</h3>
      <p>
        Al-Dawaa&rsquo;s private label strategy is narrower but strategically
        focused. Their own-brand products concentrate in personal care,
        hygiene, and wellness supplements &mdash; specifically in
        high-volume, high-frequency categories where brand switching costs
        for consumers are low. Hand sanitizers, cotton products, basic
        supplements, and personal hygiene items are the categories where
        Al-Dawaa&rsquo;s house brands have gained the most traction.
      </p>
      <p>
        Al-Dawaa&rsquo;s approach is less about building a comprehensive
        private label portfolio and more about capturing margin in commodity
        categories where branded differentiation is weakest. For branded
        companies competing in these categories, the strategic implication
        is that Al-Dawaa is less likely to challenge your premium, specialized
        products &mdash; but your commodity-tier SKUs are directly in the
        crosshairs.
      </p>

      <h3>Kunooz Pharmacy</h3>
      <p>
        Kunooz is a smaller chain compared to Nahdi and Al-Dawaa, but it is
        worth watching. Their private label activity has been more selective,
        focusing on personal care and basic health products where they can
        offer meaningful savings. Kunooz&rsquo;s approach reflects a common
        strategy among mid-tier chains: use private label as a margin tool
        in categories where branded competition is most intense and price
        sensitivity is highest, rather than attempting to build a
        comprehensive own-brand portfolio across the store.
      </p>

      <div className="table-wrapper">
        <table>
          <thead>
            <tr>
              <th>Chain</th>
              <th>Private Label Approach</th>
              <th>Focus Categories</th>
              <th>Pricing vs. Branded</th>
              <th>Maturity Level</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td>Nahdi</td>
              <td>Comprehensive, data-driven</td>
              <td>Vitamins, supplements, personal care, baby, beauty</td>
              <td>25&ndash;35% below</td>
              <td>Advanced</td>
            </tr>
            <tr>
              <td>Al-Dawaa</td>
              <td>Focused, high-frequency categories</td>
              <td>Personal care, hygiene, wellness supplements</td>
              <td>20&ndash;30% below</td>
              <td>Growing</td>
            </tr>
            <tr>
              <td>Kunooz</td>
              <td>Selective, margin-focused</td>
              <td>Personal care, basic health products</td>
              <td>20&ndash;30% below</td>
              <td>Emerging</td>
            </tr>
          </tbody>
        </table>
      </div>

      <hr />

      <h2>Marketing Strategies to Defend Against Private Label</h2>
      <p>
        Knowing the threat is not enough. You need a tactical playbook. Here
        are the specific marketing strategies that I have seen work in the
        GCC pharmacy context &mdash; strategies that go beyond generic advice
        and address the unique dynamics of this market.
      </p>

      <h3>1. HCP Recommendation Programs</h3>
      <p>
        In KSA, the pharmacist&rsquo;s recommendation is the single most
        powerful influence on OTC purchase decisions. A pharmacist who
        actively recommends your branded product over the store&rsquo;s own
        brand is the strongest defense you can have. Invest in pharmacist
        education programs that give them clinical reasons to recommend your
        product. Provide concise clinical data summaries they can reference.
        Create CME (continuing medical education) partnerships that position
        your brand as the scientifically credible choice. The pharmacist is
        your last line of defense at the point of purchase &mdash; invest in
        that relationship accordingly.
      </p>

      <h3>2. In-Store Visibility and Shopper Marketing</h3>
      <p>
        Private label benefits from preferential shelf placement &mdash; the
        retailer controls the planogram. You cannot control where your product
        sits on the shelf, but you can invest in visibility that intercepts
        the shopper before they reach the private label alternative. Gondola
        end displays, digital screen advertising within the pharmacy, counter
        displays near checkout, and point-of-sale materials that communicate
        your clinical credentials &mdash; these are the tactical tools that
        offset shelf placement disadvantage. Negotiate these placements as
        part of your trade terms, and treat them as non-negotiable budget
        items, not discretionary spending.
      </p>

      <h3>3. Consumer Education Campaigns</h3>
      <p>
        Create content that educates consumers about what differentiates your
        product without explicitly naming private label as the competitor. A
        campaign that explains why bioavailability matters in a Vitamin D
        supplement, or what to look for in a quality multivitamin, implicitly
        highlights the advantages of your branded product. This approach
        works across social media, in-app advertising on pharmacy platforms,
        and your owned digital channels. The goal is to create informed
        consumers who understand that not all products in a category are
        equal &mdash; even if the ingredient list looks similar.
      </p>

      <h3>4. Loyalty and Subscription Models</h3>
      <p>
        Reduce the consumer&rsquo;s incentive to switch by locking in repeat
        purchases before they reach the pharmacy shelf. Direct-to-consumer
        subscription models for supplements, auto-refill programs through
        e-pharmacy platforms, and exclusive offers for repeat purchasers all
        create switching friction. If a consumer is already subscribed to a
        90-day auto-delivery of your branded Vitamin D, the private label
        alternative on the shelf is irrelevant. Several DTC supplement brands
        globally have proven this model works, and the same principles apply
        in the GCC through platforms like Nahdi Online and other e-pharmacies.
      </p>

      <h3>5. Pack Size and Format Innovation</h3>
      <p>
        One underutilized strategy is making direct price comparison
        difficult. Offer pack sizes, dosage forms, or product combinations
        that private label does not match. A branded supplement offered as a
        90-day supply in convenient daily sachets is harder to compare
        directly to a private label bottle of 30 tablets. Innovation in
        format, delivery mechanism, and convenience can create separation
        that pure formulation cannot. I have seen brands successfully use
        effervescent tablets, gummy formats, and combination packs to
        differentiate against private label in categories where the base
        formulation is identical.
      </p>

      <h3>6. Digital Shelf Optimization</h3>
      <p>
        On e-pharmacy platforms, private label products often benefit from
        algorithmic priority &mdash; the chain&rsquo;s own products appear
        first in search results and category listings. Branded companies need
        to invest in digital shelf optimization: keyword-rich product titles,
        enhanced product content with clinical claims, high-quality imagery,
        and ratings and review management. The digital shelf is increasingly
        where the purchase decision is made, and losing visibility online is
        as damaging as losing shelf space in-store.
      </p>

      <p>
        For marketers looking for frameworks and peer discussion on defending
        brand share against private label, the{" "}
        <Link href="/community">PharmaGrowth community</Link> is where GCC
        pharma marketers share real-world strategies and results.
      </p>

      <hr />

      <h2>Co-Manufacturing as an Opportunity</h2>
      <p>
        Here is a perspective that many branded companies resist but should
        seriously consider: if you cannot beat private label, you can profit
        from it. Co-manufacturing &mdash; producing private label products
        for pharmacy chains &mdash; is not surrender. It is a strategic
        decision that can strengthen your business in several ways.
      </p>

      <h3>Why Consider Co-Manufacturing</h3>
      <ul>
        <li>
          <strong>Manufacturing capacity utilization.</strong> If your
          production facility has excess capacity, manufacturing private label
          products for a chain fills that capacity, reduces your per-unit
          fixed costs, and generates incremental revenue. The alternative
          &mdash; idle capacity &mdash; is a pure cost.
        </li>
        <li>
          <strong>Relationship deepening.</strong> A chain that relies on you
          to produce its private label products has a vested interest in
          maintaining a strong commercial relationship with you. This
          relationship can translate into better trade terms, preferential
          shelf space for your branded products, and early insight into the
          chain&rsquo;s category strategy.
        </li>
        <li>
          <strong>Competitive intelligence.</strong> When you manufacture the
          private label product, you know its exact formulation, its cost
          structure, and its margin profile. This intelligence is invaluable
          for positioning your branded product against it.
        </li>
        <li>
          <strong>Market entry strategy.</strong> For companies entering the
          GCC market, co-manufacturing for a major chain can serve as a
          low-risk entry point. You build manufacturing credibility, establish
          regulatory compliance, and develop channel relationships &mdash; all
          while generating revenue.
        </li>
      </ul>

      <h3>The Risks to Manage</h3>
      <p>
        Co-manufacturing is not without risks. The most significant is
        cannibalization &mdash; the private label product you manufacture may
        directly compete with your branded product on the same shelf. Managing
        this requires careful portfolio segmentation. Your branded products
        should occupy a clearly differentiated premium tier with genuine
        product advantages that the private label version (even though you
        made it) does not replicate. If you are manufacturing the exact same
        product under two labels, you are creating a problem for yourself.
      </p>
      <p>
        There is also the reputational risk if consumers discover that the
        same factory produces both the premium branded product and the
        budget private label version. In healthcare categories, this can
        undermine the premium positioning you are trying to protect. The
        mitigation is to ensure genuine formulation or quality differences
        between your branded and private label production lines.
      </p>

      <div className="takeaway">
        <p>
          <strong>Actionable takeaway:</strong> If you have manufacturing
          capabilities, evaluate the co-manufacturing opportunity
          objectively. Model the financial impact on your P&amp;L,
          including potential cannibalization effects. In many cases, the
          incremental revenue and relationship benefits outweigh the risks
          &mdash; particularly if your branded products have genuine
          differentiation that the private label version does not match.
        </p>
      </div>

      <p>
        For a deeper strategic conversation about portfolio decisions like
        this, explore the{" "}
        <Link href="/coaching">PharmaGrowth coaching programs</Link> where
        we work through these trade-offs with experienced pharma leaders.
      </p>

      <hr />

      <h2>Frequently Asked Questions</h2>

      <h3 className="faq-question">
        What is private label in the healthcare and pharmacy context?
      </h3>
      <p>
        Private label in healthcare refers to products manufactured by a
        third-party contract manufacturer but sold under the pharmacy
        chain&rsquo;s own brand name. The retailer owns the brand, controls
        the marketing, sets the price, and captures the margin. Examples
        include Nahdi-branded vitamins, Al-Dawaa house-brand personal care
        products, and similar own-brand ranges offered by pharmacy chains
        across the GCC. These products must meet the same SFDA regulatory
        requirements as branded alternatives.
      </p>

      <h3 className="faq-question">
        Which product categories are most at risk from private label in
        KSA pharmacies?
      </h3>
      <p>
        The most vulnerable categories are those perceived as commodities
        with low brand differentiation: vitamins and basic supplements,
        personal care and hygiene products, basic oral care, first aid
        supplies, and baby care essentials. Categories with strong clinical
        differentiation, patented active ingredients, and healthcare
        professional endorsement &mdash; such as specialized dermocosmetics
        and prescription-adjacent OTC products &mdash; remain more
        protected.
      </p>

      <h3 className="faq-question">
        How can branded pharma companies compete against pharmacy private
        label products?
      </h3>
      <p>
        The most effective strategies include investing in genuine product
        differentiation that private label cannot replicate, leading with
        clinical evidence and scientific credibility, building healthcare
        professional recommendation programs, investing in digital consumer
        relationships and content marketing, and innovating in pack sizes
        and delivery formats that make direct price comparison difficult.
        Price-cutting alone is not a sustainable defense &mdash; it erodes
        margins without building long-term competitive advantage.
      </p>

      <h3 className="faq-question">
        Is co-manufacturing private label products for pharmacy chains a
        good strategy?
      </h3>
      <p>
        It depends on your strategic position. Co-manufacturing can fill
        excess manufacturing capacity, deepen relationships with key
        accounts, provide competitive intelligence, and generate incremental
        revenue. However, it carries risks of cannibalization and brand
        perception damage if not managed carefully. The key is ensuring your
        branded products have genuine differentiation that the private label
        version does not replicate, so the two lines serve different consumer
        segments rather than competing directly.
      </p>

      <h3 className="faq-question">
        How is the KSA private label landscape expected to evolve over the
        next five years?
      </h3>
      <p>
        Private label penetration in GCC healthcare categories is expected
        to grow from an estimated 8&ndash;14% today to 20&ndash;25% within
        five to seven years, following patterns seen in mature markets like
        the US and UK. Key drivers include e-pharmacy growth (where
        algorithms can prioritize own-brand products), local manufacturing
        expansion under Vision 2030, premiumization of private label into
        mid-tier and premium segments, and increasingly sophisticated
        data-driven category management by major pharmacy chains.
      </p>

      <hr />

      <h2>Conclusion</h2>
      <p>
        Private label in healthcare is not a threat to be feared &mdash; it
        is a competitive reality to be managed. The pharmacy chains building
        their own brands are responding to genuine consumer demand for
        accessible, affordable healthcare products. They are not doing
        anything wrong. They are doing it well, and they are getting better
        at it every year.
      </p>
      <p>
        The burden falls on branded companies to justify their premium. That
        justification cannot rest on historical market position or brand
        inertia alone. It must be grounded in genuine product superiority,
        clinical evidence, brand equity that consumers can feel, and
        marketing that communicates value in terms that matter to the
        consumer standing in the pharmacy aisle, comparing two products
        side by side.
      </p>
      <p>
        I have seen too many branded companies respond to private label
        with denial, then panic pricing, then margin erosion that makes the
        business unsustainable. The companies that navigate this transition
        successfully treat private label as a catalyst for raising their own
        game &mdash; innovating harder, marketing smarter, and building
        deeper relationships with both consumers and the healthcare
        professionals who influence them.
      </p>
      <p>
        The GCC healthcare market is growing rapidly. There is room for both
        branded and private label products to thrive. But room does not mean
        guaranteed. You have to earn it every day, at every shelf, in every
        pharmacy.
      </p>
      <p>
        If you are navigating the private label challenge and want access to
        strategic frameworks, peer discussion, and direct coaching from
        experienced GCC pharma leaders, join the{" "}
        <Link href="/community">PharmaGrowth community</Link>. It is where
        pharmaceutical marketing professionals across the MENA region come
        together to share strategies, solve real business problems, and
        accelerate their growth.
      </p>

      <hr />

      <p>
        <em>
          Sherif Al-Kady is a pharmaceutical marketing strategist with 20+
          years of experience building consumer healthcare and dermocosmetic
          brands across the GCC and MENA region. He is the founder of
          PharmaGrowth, a platform dedicated to helping pharma marketers grow
          their brands and careers through strategic excellence.
        </em>
      </p>
    </ArticleLayout>
  );
}
